Navigation Links
Elekta and Philips Gain MD Anderson Cancer Center as Collaborator in Research Consortium on MRI-Guided Radiation Therapy
Date:1/24/2013

r during radiation therapy could provide the health care team the ability to optimize treatment while reducing toxicity," says Steven J. Frank , M.D., Associate Professor of Radiation Oncology and Director of Advanced Technologies at MD Anderson. "Our collaborative research will focus on what this combination could mean for patients in the future."

"The development of a meaningful, yet complex innovation like the MRI-guided radiation therapy system can only be done in partnership with leading healthcare innovators, both from an industrial, as well as a clinical perspective," says Gene Saragnese , CEO Imaging Systems at Philips Healthcare. "As a leading innovator in cancer care, the University of Texas MD Anderson Cancer Center will bring their unique expertise to help realize the promise of more targeted cancer treatments and transform the way healthcare is delivered today."

Prior to the establishment of the research consortium, Elekta, Philips and the University Medical Center Utrecht have built and tested a prototype system that integrates a linear accelerator and a 1.5 Tesla MRI system. The success of these efforts has enabled the project to move to the next phase of development and testing by the select group of consortium partners.

Radiation therapy and medical imaging already play an essential role in treatment planning, delivery and after care, and are proven, cost-effective and safe methods for the treatment of individuals with cancer. Radiotherapy is a critical modality for cancer treatment, either as a frontline treatment or used with other modalities, such as chemotherapy. The procedure involves identifying cancerous tissue and irradiating it with high-energy radiation beams in a way that maximizes sparing of healthy tissues near the tumor.  

The integrated MRI-guided radiation therapy system is in development and not available for sale.

For further
'/>"/>

SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
2. Elekta President and CEO Tomas Puusepp Pledges Support in Addressing Global Cancer Challenge at World Cancer Leaders Summit in Montreal
3. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
4. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
5. Find New Cancer Treatments at cureLauncher
6. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
7. New Shared Synthetic Replikin Cancer Vaccines
8. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
9. Genetic basis of high-risk childhood cancer points to possible new drug treatment strategy
10. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
11. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... studies at the International Spine Intervention Society’ s 23rd Annual Scientific ... August 1st, 2015. With a focus on evidence-based research and clinical application, the ...
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/28/2015)... Brooklyn, NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of ... with their quirky humor and excellent customer service. Images such as the Fonz in ... website to add some flavor to the humdrum spectroscopy field. , FireflySci is ...
(Date:8/27/2015)... Reston, VA (PRWEB) , ... August 27, 2015 , ... ... government contractors solve complex business problems, is pleased to announce their ranking as one ... 34th annual ranking of the fastest-growing private companies across the nation. , “It is ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Mass., Sept. 28 Decision Resources, one of the ... healthcare issues finds that, owing to increasing generic availability ... from $26 billion in 2009 to $23 billion in ... United Kingdom and Japan. The Pharmacor 2010 ...
... 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... SHENZHEN, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 2Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 3Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 4Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 5Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 6Pepscan Therapeutics Announces Establishment of Scientific Advisory Board 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... a specific mutation in a gene in horses that affects ... related to racing performance and is advantageous for harness-racing horses. ... on their diversification, as the altered gait characteristics of a ... study that includes a Texas A&M University researcher. Gus ...
... roofs or in sun-drenched fields, quietly harvesting the sun,s ... green energy movement. But could they be better ... Drexel University and The University of Pennsylvania are trying ... nanotechnology and a lot of mathematical modeling. ...
... A new center at the University of Michigan will ... development at laboratories across campus. , Called the Center ... coordinate and support work in a range of departments ... the translation of early research toward patient usea gray ...
Cached Biology News:Controlling gait of horses may be possible, says key study from Texas A&M 2Soaking up the Sun 2Soaking up the Sun 3Soaking up the Sun 4Chemicals today, drugs tomorrow: U-M's new Center for Drug Discovery 2Chemicals today, drugs tomorrow: U-M's new Center for Drug Discovery 3